1,351 results on '"Chaisson, Richard E"'
Search Results
2. Improving access to tuberculosis preventive treatment for children in Ethiopia: designing a home-based contact management intervention for the CHIP-TB trial through formative research
3. A Standardized Approach for Collection of Objective Data to Support Outcome Determination for Late-Phase Tuberculosis Clinical Trials.
4. Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
5. Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
6. Restocking the tuberculosis drug arsenal
7. Association between Covishield vaccine and menstrual disturbance. Findings from a cross-sectional study among participants of Zero TB cohort in India
8. Pragmatic cluster-randomized trial of home-based preventive treatment for TB in Ethiopia and South Africa (CHIP-TB)
9. Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis
10. WHO global research priorities for antimicrobial resistance in human health
11. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
12. Tuberculosis elimination in the Asia-Pacific region and the WHO ethics guidance
13. Completion, safety, and efficacy of tuberculosis preventive treatment regimens containing rifampicin or rifapentine: an individual patient data network meta-analysis
14. Impact and cost-effectiveness of short-course tuberculosis preventive treatment for household contacts and people with HIV in 29 high-incidence countries: a modelling analysis
15. High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial
16. Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
17. Comparison of QuantiFERON Gold In-Tube Versus Tuberculin Skin Tests on the Initiation of Tuberculosis Preventive Therapy Among Patients Newly Diagnosed With HIV in the North West Province of South Africa (the Teko Study): A Cluster Randomized Trial.
18. Systemic DPP4/CD26 is associated with natural HIV-1 control: Implications for COVID-19 susceptibility
19. Cost-effectiveness of scaling up short course preventive therapy for tuberculosis among children across 12 countries
20. Human leukocyte antigen associations with protection against tuberculosis infection and disease in human immunodeficiency virus-1 infected individuals, despite household tuberculosis exposure and immune suppression
21. Pharmacokinetic-Pharmacodynamic Evidence From a Phase 3 Trial to Support Flat-Dosing of Rifampicin for Tuberculosis.
22. Once-weekly rifapentine and isoniazid for tuberculosis prevention in patients with HIV taking dolutegravir-based antiretroviral therapy: a phase 1/2 trial
23. High prevalence of rifampin-resistant tuberculosis in mountainous districts of India
24. Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
25. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
26. Post-trial perceptions of a symptom-based TB screening intervention in South Africa: implementation insights and future directions for TB preventive healthcare services
27. Overview of Tuberculosis
28. The FCGR2C allele that modulated the risk of HIV-1 infection in the Thai RV144 vaccine trial is implicated in HIV-1 disease progression
29. Cis-regulatory genetic variants in the CCR5 gene and natural HIV-1 control in black South Africans
30. Brief Report: Yield of Repeat Tuberculin Skin Testing for People Living With HIV in Brazil
31. US Guidelines Fall Short on Short-Course Tuberculosis-Preventive Therapy.
32. Adverse Pregnancy Outcomes Among Women with Human Immunodeficiency Virus Taking Isoniazid Preventive Therapy During the First Trimester.
33. US Guidelines Fall Short on Short-Course TB Preventive Therapy
34. Adverse Pregnancy Outcomes among HIV-infected Women Taking Isoniazid Preventive Therapy During the First Trimester
35. Poor Obstetric and Infant Outcomes in Human Immunodeficiency Virus-Infected Pregnant Women With Tuberculosis in South Africa : The Tshepiso Study
36. Conclusions and Future Directions
37. Tuberculosis
38. Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapine
39. Plasma Indoleamine 2, 3-Dioxygenase, a Biomarker for Tuberculosis in Human Immunodeficiency Virus-Infected Patients
40. CXCR6 gene characterization in two ethnically distinct South African populations and association with viraemic disease control in HIV-1-infected black South African individuals
41. CD4+ cell count stratification to guide tuberculosis preventive therapy for people living with HIV
42. Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV
43. High Isoniazid Exposures When Administered with Rifapentine Once Weekly for Latent Tuberculosis in Individuals with Human Immunodeficiency Virus
44. Shortening Tuberculosis Treatment With Fluoroquinolones: Lost in Translation?
45. Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection
46. Risk of developing active tuberculosis following tuberculosis screening and preventive therapy for Tibetan refugee children and adolescents in India: An impact assessment
47. Pregnancy in Women With HIV in a Tuberculosis Preventive Therapy Trial
48. Pharmacokinetics of Efavirenz and Treatment of HIV-1 Among Pregnant Women With and Without Tuberculosis Coinfection
49. Cost‐effectiveness of a 12 country‐intervention to scale up short course TB preventive therapy among people living with HIV
50. Cost‐effectiveness of one month of daily isoniazid and rifapentine versus three months of weekly isoniazid and rifapentine for prevention of tuberculosis among people receiving antiretroviral therapy in Uganda
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.